EyePoint Misses Phase 3 Goal While Amylyx Shares Jump 35%

EyePoint Pharmaceuticals disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness failed to meet its primary goal, while Amylyx shares rose 35.18% to 28.97 on the same day, according to a STAT News Pharmalittle roundup and licensed market data as of 13:51 GMT on Aug. 18, 2026.

Two biotech stories landed on the same morning tape, pulling in opposite directions. EyePoint Pharmaceuticals (EYPT) told investors that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness did not hit its primary goal. Amylyx Pharmaceuticals (AMLX), meanwhile, was on the winning side of the ledger, and the market treated it accordingly.

The disclosures were gathered in the STAT News Pharmalittle roundup on Aug. 18, 2026.

What a primary endpoint miss actually costs

A Phase 3 trial's primary endpoint is the single pre-specified measurement a sponsor agrees, in advance and usually in consultation with regulators, will define success or failure. Everything else in the study — secondary endpoints, subgroup cuts, safety data — is supporting material. When the primary goal is not met, the regulatory path narrows sharply. A company can still argue its case, but it is arguing from a weaker position, and it typically needs additional trials, additional years and additional capital to do it.

That is the calculus facing EyePoint. The lead does not specify which endpoint fell short, by how much, or what the company intends to do next, and no such detail should be assumed. What is clear is the category: a late-stage failure in retinal disease, the most fiercely contested field in ophthalmology.

Age-related macular degeneration is one of the leading causes of vision loss in older adults. The wet form is treated with repeated injections into the eye that block vascular endothelial growth factor, the protein that drives the abnormal blood vessel growth behind the damage. Those anti-VEGF injections work. Their weakness is not efficacy but burden: patients and their families face a treatment schedule measured in visits per year, indefinitely, and real-world adherence slips as a result.

Almost every next-generation program in the space is therefore competing on the same premise — match the vision outcomes of the established injections while requiring fewer of them. That is a demanding bar, because the incumbent is genuinely effective and the trials are powered to detect whether a challenger holds the line. Miss on the primary measure and the commercial argument gets difficult fast, since a treatment that is more convenient but not clearly as good is a hard sell to retina specialists who have a working option in hand.

The trading response, and a benchmark that was already red

On the licensed market data as of 13:51 GMT on Aug. 18, 2026, EYPT was quoted at 5.28, up 8.42% from a previous close of 4.87, with an intraday range of 4.70 to 5.50. The exchange and currency are not specified in the feed, so the figure is stated as quoted.

That combination — a wide intraday band from 4.70 to 5.50 and a gain of roughly 0.41 points on the session — is the signature of a stock repricing in real time rather than settling on a verdict. Trading through the low end of the range and the high end within one session says holders and buyers disagree, sharply, about what a failed primary endpoint leaves behind. Investors weighing this name should treat single-print quotes on a news day with caution; the range is the more informative number.

Amylyx moved with far less ambiguity. AMLX was quoted at 28.97, up 35.18% from a previous close of 21.43, inside a day range of 27.95 to 30.70. A move of that scale — an increase of about 7.54 points on the session, on an illustrative basis derived from the quoted prices — is what a clinical read-through looks like when the market judges it decisive rather than debatable. Notably, the stock's intraday low of 27.95 sat well above the prior close, meaning the repricing happened at the open and held.

Both moves came against a soft broad market. SPY, tracking the S&P 500, was at $768.72, down 0.51% from a prior close of $772.67. QQQ, tracking the Nasdaq 100, was weaker at $719.85, off 1.37% from $729.87. DIA was close to flat at $533.80, down 0.07%. Growth-heavy indexes leading the market lower is the usual backdrop for a session in which biotech single names trade on their own data rather than on beta.

How binary events reshape a sector's risk pricing

The pairing is a clean illustration of why clinical-stage biotech resists conventional valuation. Neither company's fundamentals changed overnight in any accounting sense. What changed was the probability the market assigns to a specific asset reaching the market — and in single-asset or narrow-pipeline companies, that probability is close to the whole equity story.

For EyePoint, the questions that matter now are procedural and financial. Does the full dataset support any regulatory conversation, or does the program require a fresh trial? How much cash runway stands behind whatever path management chooses? And does the company still hold a differentiated position in retinal disease, or does it become a bidder for someone else's asset?

For Amylyx, the follow-through questions are about conversion: what regulatory submission the result supports, on what timetable, and how much of the move already discounts an approval that has not happened.

What to watch from here

• Full data disclosure. Topline statements rarely settle the argument. Presentation of the complete EyePoint dataset at a medical meeting or in a filing will determine whether the secondary measures offer anything usable.
• Regulatory language. Any indication of a path forward — or the absence of one — is the next real catalyst for EYPT.
• Competitive read-through. Retinal programs at other sponsors are chasing the same dosing-interval prize. A failure by one entrant does not validate the others, but it does change how investors handicap the field.
• Cash and strategy. Late-stage misses commonly precede cost reductions, pipeline reprioritisation or corporate transactions.

Neither result should be read as a verdict on the underlying science. Late-stage trials fail for reasons that range from biology to trial design to the sheer difficulty of beating an incumbent that already works well. What the tape captured on Aug. 18 was not a scientific conclusion but a rapid, and in EyePoint's case unresolved, repricing of risk.

Key facts

• EYPT price: 5.28, +8.42% (as of 13:51 GMT, Aug. 18, 2026)
• AMLX price: 28.97, +35.18% (as of 13:51 GMT, Aug. 18, 2026)
• EyePoint trial: Phase 3 in a common cause of age-related blindness missed primary goal
• Market backdrop: SPY $768.72 (-0.51%), QQQ $719.85 (-1.37%), DIA $533.80 (-0.07%)

Frequently asked questions

What did EyePoint disclose?

EyePoint Pharmaceuticals disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal. The disclosure was reported in STAT News's Pharmalittle roundup on Aug. 18, 2026. The company has not, in the reported material, specified the size of the shortfall or its next regulatory step.

How did the two stocks trade on the news?

On licensed market data as of 13:51 GMT on Aug. 18, 2026, EYPT was quoted at 5.28, up 8.42% from a prior close of 4.87, having traded between 4.70 and 5.50. AMLX was quoted at 28.97, up 35.18% from a prior close of 21.43, with a day range of 27.95 to 30.70.

Why does missing a primary endpoint matter so much?

The primary endpoint is the single pre-specified measure that defines whether a Phase 3 trial succeeded. Regulators weigh it most heavily. Missing it usually means a sponsor cannot rely on that study alone for approval and may need further trials, adding years of development time and additional capital before the asset can reach patients.

What is the current standard of care in wet age-related macular degeneration?

Wet AMD is treated with repeated injections into the eye that block vascular endothelial growth factor, the protein driving abnormal blood vessel growth. These anti-VEGF drugs are effective, but they require ongoing clinic visits indefinitely. Reducing that treatment burden while preserving vision outcomes is the goal most next-generation retinal programs are chasing.

Was the broader market up or down that session?

Lower, led by growth. SPY, tracking the S&P 500, stood at $768.72, down 0.51% from a prior close of $772.67. QQQ, tracking the Nasdaq 100, was at $719.85, down 1.37% from $729.87. DIA was nearly flat at $533.80, off 0.07%. Both biotech moves ran against that backdrop.

What should investors watch next?

Full dataset disclosure from EyePoint at a medical meeting or in a filing, any signal on the regulatory path forward, the company's cash runway and strategic response, and read-through to rival retinal programs. For Amylyx, the follow-through is whether the result converts into a regulatory submission and on what timetable.

Sources

• STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more — STAT News

Photo: cottonbro studio · Pexels Licence — source